NCT03821272 2025-10-08
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
Phase 1/2 Completed
University of Arkansas
National Institutes of Health Clinical Center (CC)
Halozyme Therapeutics
Merck KGaA, Darmstadt, Germany
Arya, Vijaypal, M.D., P.C.
BioRegen Biomedical (CHangzhou) Co., Ltd
Xiangya Hospital of Central South University